Drug profile · INN
afatinib dimaleate
GILOTRIF
afatinib dimaleate (GILOTRIF) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — afatinib dimaleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
afatinib dimaleate (GILOTRIF) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is afatinib dimaleate?
afatinib dimaleate (GILOTRIF) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for afatinib dimaleate?
GILOTRIF is a marketed brand name for afatinib dimaleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of afatinib dimaleate?
afatinib dimaleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.